Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PALB2 L1142Yfs*21 |
| Therapy | Olaparib |
| Indication/Tumor Type | breast carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 L1142Yfs*21 | breast carcinoma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a Phase II trial, treatment with Lynparza (olaparib) resulted in an objective response rate of 25.0% (2/8) and clinical benefit rate of 50.0% in advanced solid tumor patients harboring PALB2 mutations, including a partial response in a patient with breast carcinoma harboring PALB2 L1142Yfs*21 (reported as c.3424del) (PMID: 42105598). | 42105598 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42105598) | Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2. | Full reference... |